CT-G11

CT-G11 is a small molecule drug developed by Celltrion, Inc. It was investigated primarily for cardiovascular diseases, specifically hypertrophic cardiomyopathy and hypertrophic obstructive cardiomyopathy. The drug underwent early clinical development but its highest development phase reached was Phase 1 before being discontinued. The exact mechanism of action and molecular targets are not detailed in the available data. CT-G11 was studied in randomized, double-blind, placebo-controlled Phase 1 trials to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers and patients with obstructive hypertrophic cardiomyopathy[1][4].